BioCryst Pharmaceuticals Appoints Sandeep M. Menon as Chief Research and Development Officer
Key Insights
BioCryst Pharmaceuticals has appointed Dr. Sandeep M. Menon as Chief Research and Development Officer, bringing extensive experience from Alnylam Pharmaceuticals (search) and Pfizer.
Dr. Menon previously led the FDA approval of AMVUTTRA (vutrisiran) for ATTR cardiomyopathy (search) at Alnylam and co-led the rapid development of PAXLOVID at Pfizer.
The appointment comes as BioCryst advances navenibart toward a potential BLA submission and expands its rare disease pipeline following the Astria Therapeutics (search) acquisition.
BioCryst Pharmaceuticals has appointed Dr. Sandeep M. Menon as Chief Research and Development Officer, marking a strategic leadership addition as the rare disease-focused biotechnology company enters a new phase of growth. The appointment comes as BioCryst builds on the commercial success of ORLADEYO and the recent acquisition of Astria Therapeutics (search) and its navenibart program.
Proven Track Record in Drug Development
Dr. Menon joins BioCryst from Alnylam Pharmaceuticals (search), where he served as Chief Development Officer, overseeing global clinical development and safety across multiple therapeutic areas. Under his leadership, his team secured FDA approval of AMVUTTRA (vutrisiran), a novel RNAi therapeutic for ATTR cardiomyopathy (search), and advanced multiple programs through key clinical milestones.
"As BioCryst enters a critical phase, our priority is disciplined drug development and flawless regulatory delivery for innovative therapies that can change patients' lives," said Charlie Gayer, President and Chief Executive Officer of BioCryst. "Sandeep brings a proven record of leading complex programs through approval, scaling global R&D organizations, and making tough, value-driven decisions."
Extensive Pharmaceutical Experience
Prior to Alnylam, Dr. Menon spent over a decade at Pfizer in senior R&D leadership roles, most recently as Senior Vice President, Head of Early Clinical Development and Chief Scientific Officer, BioMedicine AI and Digital Sciences. He led large, global development organizations and played a key role in improving R&D success rates across the portfolio.
Notably, Dr. Menon co-led the clinical development of PAXLOVID, which achieved a remarkable timeline progression from first-in-human dosing to emergency use authorization in nine months. He also contributed to the development and approval of multiple therapies across oncology, immunology and rare disease.
Earlier in his career, Dr. Menon held clinical development and biostatistics leadership roles at Biogen Idec (search) and Aptiv Solutions (ICON).
Strategic Focus on Rare Disease Pipeline
The appointment aligns with BioCryst's strategic priorities as the company advances navenibart toward a potential BLA submission. "With navenibart advancing toward a potential BLA and a growing pipeline behind it, his leadership strengthens our ability to sharpen our R&D strategy, balance capital allocation and risk, and create durable long-term value through repeated rare disease launches," Gayer noted.
Dr. Menon expressed enthusiasm about joining the company at this critical juncture. "BioCryst is at a critical inflection point in its history and I am excited to join as the company enters its next stage of growth," he said. "BioCryst has built a growing rare disease business with strong commercial momentum, a differentiated portfolio, and a clear path to expand it."
Academic and Professional Credentials
Dr. Menon brings extensive academic credentials to his new role, holding a PhD in Biostatistics and an MPH in Epidemiology and Biostatistics from Boston University, an MS in Translational Pharmacology from The Ohio State University, and a medical degree from Karnataka University in India.
BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (search) (HAE) and other rare diseases. The company has commercialized ORLADEYO (berotralstat), the first oral, once-daily plasma kallikrein (search) inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for rare diseases.